Fosrolapitant Combined With Palonosetron to Prevent Trastuzumab Rezetecan Related CINV

NCT07726433 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Chemotherapy-Induced Nausea and Vomiting (CINV)

Interventions

DRUG: Fosrolapitant and Palonosetron Hydrochloride for Injection

Sponsor

Tianjin Medical University Cancer Institute and Hospital